Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572121 | 1.00 | TLR4 (0.48) | TLR4TLR2SIRT2PARP10PARP15 | |
| SCHEMBL16602104 | 1.00 | TLR4 (0.48) | TLR4TLR2SIRT2PARP10PARP15 | |
| SCHEMBL29818895 | 1.00 | TLR4 (0.48) | TLR4TLR2SIRT2PARP10PARP15 | |
| SCHEMBL29818904 | 1.00 | TLR4 (0.48) | TLR4TLR2SIRT2PARP10PARP15 | |
| SCHEMBL2206412 | 1.00 | TLR4 (0.48) | TLR4TLR2SIRT2PARP10PARP15 | |
| SCHEMBL2206408 | 1.00 | TLR4 (0.48) | TLR4TLR2SIRT2PARP10PARP15 | |
| SCHEMBL2206874 | 1.00 | TLR4 (0.48) | TLR4TLR2SIRT2PARP10PARP15 | |
| SCHEMBL15150948 | 1.00 | TLR4 (0.48) | TLR4TLR2SIRT2PARP10PARP15 | |
| SCHEMBL2209121 | 0.99 | TLR4 (0.46) | TLR4TLR2SIRT2PARP10PARP15 | |
| SCHEMBL2206480 | 0.99 | TLR4 (0.46) | TLR4TLR2SIRT2PARP10PARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| EP-3210966-A1 | ALKOXYPHENYLPROPYLAMINES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Acucela, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2017-02-23 | — | — | US | disclosed |
| EP-2091955-B1 | Alkoxyphenylpropylamines for the treatment of age-related macular degeneration | ACUCELA INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9458088-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150239836-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239825-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-9079825-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-8993807-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8981153-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8829244-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239836-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885SIRT2 923/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885SIRT2 923/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TLR4 517/4885TLR2 890/4885SIRT2 903/4885 |
| US-20150239825-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885SIRT2 923/4885 |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885SIRT2 923/4885 |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885SIRT2 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.